Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > We knew that was coming !!!
View:
Post by MrMugsy on Apr 27, 2022 3:15pm

We knew that was coming !!!

Pressure is on to solve chronic ... which leads us into IBD and Aspirin.

We knew this type of warning was coming.
Already getting it on the opioid side - about time we're getting it on the NSAID side.

And no - I'm not asking for anyone to push the price up ... Mugsy don't work like that !!!
He speaking to long term holders.

: )

https://www.cnn.com/videos/health/2022/04/26/aspirin-heart-health-recommendation-gupta-ath-vpx.cnn
Comment by themagicbox on Apr 27, 2022 4:11pm
Honestly, if Otena hits the market today, I would have no issues taking the drug now. The SE we've seen thus far is hardly comparable to whats on the market. IMO its all about appeasing the FDA regulartors, or as Stauffer calls them, "masters".  But Mugs have you read anything into new h2s moeities? I am thinking they create a new dosing regimin like we discussed before or use ...more  
Comment by MrMugsy on Apr 27, 2022 5:17pm
Not specifically, but there is new chemistry for IBD and I think there are a few different angles being studied there.  We just don't know the details. I also think what they learn from the IBD chemistry will serve as a blueprint for developing 340. But ...  On the release side - I'm still betting that we don't need to worry about it for 346 - chronic. They have ideas on ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities